0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Genetic Disorders Drug Market Research Report 2025
Published Date: August 2025
|
Report Code: QYRE-Auto-23Q8526
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Genetic Disorders Drug Market Insights and Forecast to 2028
BUY CHAPTERS

Global Genetic Disorders Drug Market Research Report 2025

Code: QYRE-Auto-23Q8526
Report
August 2025
Pages:81
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Genetic Disorders Drug Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Genetic Disorders Drug Market

Genetic Disorders Drug Market

The global market for Genetic Disorders Drug was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Genetic Disorders Drugs are genetic materials such as DNA and RNA delivered into the body as a therapeutic. They are a promising new class of medicine that was not possible even a short time ago.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Genetic Disorders Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Genetic Disorders Drug.
The Genetic Disorders Drug market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Genetic Disorders Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Genetic Disorders Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Genetic Disorders Drug Market Report

Report Metric Details
Report Name Genetic Disorders Drug Market
CAGR 5%
Segment by Type
  • Cystic Fibrosis (CF)
  • Duchenne Muscular Dystrophy (DMD)
  • Lysosomal Storage Disease (LSD)
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
Segment by Application
  • Clinic
  • Hospital
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Sanofi, Vertex, Takeda, Amgen, GW Pharmaceuticals, Pfizer, BioMarin, Sarepta
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Genetic Disorders Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Genetic Disorders Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Genetic Disorders Drug Market report?

Ans: The main players in the Genetic Disorders Drug Market are Sanofi, Vertex, Takeda, Amgen, GW Pharmaceuticals, Pfizer, BioMarin, Sarepta

What are the Application segmentation covered in the Genetic Disorders Drug Market report?

Ans: The Applications covered in the Genetic Disorders Drug Market report are Clinic, Hospital

What are the Type segmentation covered in the Genetic Disorders Drug Market report?

Ans: The Types covered in the Genetic Disorders Drug Market report are Cystic Fibrosis (CF), Duchenne Muscular Dystrophy (DMD), Lysosomal Storage Disease (LSD), Paroxysmal Nocturnal Hemoglobinuria (PNH)

1 Genetic Disorders Drug Market Overview
1.1 Product Definition
1.2 Genetic Disorders Drug by Type
1.2.1 Global Genetic Disorders Drug Market Value Comparison by Type (2024 VS 2031)
1.2.2 Cystic Fibrosis (CF)
1.2.3 Duchenne Muscular Dystrophy (DMD)
1.2.4 Lysosomal Storage Disease (LSD)
1.2.5 Paroxysmal Nocturnal Hemoglobinuria (PNH)
1.3 Genetic Disorders Drug by Application
1.3.1 Global Genetic Disorders Drug Market Value by Application (2024 VS 2031)
1.3.2 Clinic
1.3.3 Hospital
1.4 Global Genetic Disorders Drug Market Size Estimates and Forecasts
1.4.1 Global Genetic Disorders Drug Revenue 2020-2031
1.4.2 Global Genetic Disorders Drug Sales 2020-2031
1.4.3 Global Genetic Disorders Drug Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Genetic Disorders Drug Market Competition by Manufacturers
2.1 Global Genetic Disorders Drug Sales Market Share by Manufacturers (2020-2025)
2.2 Global Genetic Disorders Drug Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Genetic Disorders Drug Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Genetic Disorders Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Genetic Disorders Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Genetic Disorders Drug, Product Type & Application
2.7 Global Key Manufacturers of Genetic Disorders Drug, Date of Enter into This Industry
2.8 Global Genetic Disorders Drug Market Competitive Situation and Trends
2.8.1 Global Genetic Disorders Drug Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Genetic Disorders Drug Players Market Share by Revenue
2.8.3 Global Genetic Disorders Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Genetic Disorders Drug Market Scenario by Region
3.1 Global Genetic Disorders Drug Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Genetic Disorders Drug Sales by Region: 2020-2031
3.2.1 Global Genetic Disorders Drug Sales by Region: 2020-2025
3.2.2 Global Genetic Disorders Drug Sales by Region: 2026-2031
3.3 Global Genetic Disorders Drug Revenue by Region: 2020-2031
3.3.1 Global Genetic Disorders Drug Revenue by Region: 2020-2025
3.3.2 Global Genetic Disorders Drug Revenue by Region: 2026-2031
3.4 North America Genetic Disorders Drug Market Facts & Figures by Country
3.4.1 North America Genetic Disorders Drug Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Genetic Disorders Drug Sales by Country (2020-2031)
3.4.3 North America Genetic Disorders Drug Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Genetic Disorders Drug Market Facts & Figures by Country
3.5.1 Europe Genetic Disorders Drug Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Genetic Disorders Drug Sales by Country (2020-2031)
3.5.3 Europe Genetic Disorders Drug Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Genetic Disorders Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Genetic Disorders Drug Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Genetic Disorders Drug Sales by Region (2020-2031)
3.6.3 Asia Pacific Genetic Disorders Drug Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Genetic Disorders Drug Market Facts & Figures by Country
3.7.1 Latin America Genetic Disorders Drug Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Genetic Disorders Drug Sales by Country (2020-2031)
3.7.3 Latin America Genetic Disorders Drug Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Genetic Disorders Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Genetic Disorders Drug Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Genetic Disorders Drug Sales by Country (2020-2031)
3.8.3 Middle East and Africa Genetic Disorders Drug Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Genetic Disorders Drug Sales by Type (2020-2031)
4.1.1 Global Genetic Disorders Drug Sales by Type (2020-2025)
4.1.2 Global Genetic Disorders Drug Sales by Type (2026-2031)
4.1.3 Global Genetic Disorders Drug Sales Market Share by Type (2020-2031)
4.2 Global Genetic Disorders Drug Revenue by Type (2020-2031)
4.2.1 Global Genetic Disorders Drug Revenue by Type (2020-2025)
4.2.2 Global Genetic Disorders Drug Revenue by Type (2026-2031)
4.2.3 Global Genetic Disorders Drug Revenue Market Share by Type (2020-2031)
4.3 Global Genetic Disorders Drug Price by Type (2020-2031)
5 Segment by Application
5.1 Global Genetic Disorders Drug Sales by Application (2020-2031)
5.1.1 Global Genetic Disorders Drug Sales by Application (2020-2025)
5.1.2 Global Genetic Disorders Drug Sales by Application (2026-2031)
5.1.3 Global Genetic Disorders Drug Sales Market Share by Application (2020-2031)
5.2 Global Genetic Disorders Drug Revenue by Application (2020-2031)
5.2.1 Global Genetic Disorders Drug Revenue by Application (2020-2025)
5.2.2 Global Genetic Disorders Drug Revenue by Application (2026-2031)
5.2.3 Global Genetic Disorders Drug Revenue Market Share by Application (2020-2031)
5.3 Global Genetic Disorders Drug Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Sanofi
6.1.1 Sanofi Company Information
6.1.2 Sanofi Description and Business Overview
6.1.3 Sanofi Genetic Disorders Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Sanofi Genetic Disorders Drug Product Portfolio
6.1.5 Sanofi Recent Developments/Updates
6.2 Vertex
6.2.1 Vertex Company Information
6.2.2 Vertex Description and Business Overview
6.2.3 Vertex Genetic Disorders Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Vertex Genetic Disorders Drug Product Portfolio
6.2.5 Vertex Recent Developments/Updates
6.3 Takeda
6.3.1 Takeda Company Information
6.3.2 Takeda Description and Business Overview
6.3.3 Takeda Genetic Disorders Drug Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Takeda Genetic Disorders Drug Product Portfolio
6.3.5 Takeda Recent Developments/Updates
6.4 Amgen
6.4.1 Amgen Company Information
6.4.2 Amgen Description and Business Overview
6.4.3 Amgen Genetic Disorders Drug Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Amgen Genetic Disorders Drug Product Portfolio
6.4.5 Amgen Recent Developments/Updates
6.5 GW Pharmaceuticals
6.5.1 GW Pharmaceuticals Company Information
6.5.2 GW Pharmaceuticals Description and Business Overview
6.5.3 GW Pharmaceuticals Genetic Disorders Drug Sales, Revenue and Gross Margin (2020-2025)
6.5.4 GW Pharmaceuticals Genetic Disorders Drug Product Portfolio
6.5.5 GW Pharmaceuticals Recent Developments/Updates
6.6 Pfizer
6.6.1 Pfizer Company Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Genetic Disorders Drug Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Pfizer Genetic Disorders Drug Product Portfolio
6.6.5 Pfizer Recent Developments/Updates
6.7 BioMarin
6.7.1 BioMarin Company Information
6.7.2 BioMarin Description and Business Overview
6.7.3 BioMarin Genetic Disorders Drug Sales, Revenue and Gross Margin (2020-2025)
6.7.4 BioMarin Genetic Disorders Drug Product Portfolio
6.7.5 BioMarin Recent Developments/Updates
6.8 Sarepta
6.8.1 Sarepta Company Information
6.8.2 Sarepta Description and Business Overview
6.8.3 Sarepta Genetic Disorders Drug Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Sarepta Genetic Disorders Drug Product Portfolio
6.8.5 Sarepta Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Genetic Disorders Drug Industry Chain Analysis
7.2 Genetic Disorders Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Genetic Disorders Drug Production Mode & Process Analysis
7.4 Genetic Disorders Drug Sales and Marketing
7.4.1 Genetic Disorders Drug Sales Channels
7.4.2 Genetic Disorders Drug Distributors
7.5 Genetic Disorders Drug Customer Analysis
8 Genetic Disorders Drug Market Dynamics
8.1 Genetic Disorders Drug Industry Trends
8.2 Genetic Disorders Drug Market Drivers
8.3 Genetic Disorders Drug Market Challenges
8.4 Genetic Disorders Drug Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Genetic Disorders Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Genetic Disorders Drug Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Genetic Disorders Drug Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Genetic Disorders Drug Sales (K Doses) of Key Manufacturers (2020-2025)
 Table 5. Global Genetic Disorders Drug Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Genetic Disorders Drug Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Genetic Disorders Drug Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Genetic Disorders Drug Average Price (USD/Dose) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Genetic Disorders Drug, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Genetic Disorders Drug, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Genetic Disorders Drug, Product Type & Application
 Table 12. Global Key Manufacturers of Genetic Disorders Drug, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Genetic Disorders Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Genetic Disorders Drug as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Genetic Disorders Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Genetic Disorders Drug Sales by Region (2020-2025) & (K Doses)
 Table 18. Global Genetic Disorders Drug Sales Market Share by Region (2020-2025)
 Table 19. Global Genetic Disorders Drug Sales by Region (2026-2031) & (K Doses)
 Table 20. Global Genetic Disorders Drug Sales Market Share by Region (2026-2031)
 Table 21. Global Genetic Disorders Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Genetic Disorders Drug Revenue Market Share by Region (2020-2025)
 Table 23. Global Genetic Disorders Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Genetic Disorders Drug Revenue Market Share by Region (2026-2031)
 Table 25. North America Genetic Disorders Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Genetic Disorders Drug Sales by Country (2020-2025) & (K Doses)
 Table 27. North America Genetic Disorders Drug Sales by Country (2026-2031) & (K Doses)
 Table 28. North America Genetic Disorders Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Genetic Disorders Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Genetic Disorders Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Genetic Disorders Drug Sales by Country (2020-2025) & (K Doses)
 Table 32. Europe Genetic Disorders Drug Sales by Country (2026-2031) & (K Doses)
 Table 33. Europe Genetic Disorders Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Genetic Disorders Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Genetic Disorders Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Genetic Disorders Drug Sales by Region (2020-2025) & (K Doses)
 Table 37. Asia Pacific Genetic Disorders Drug Sales by Region (2026-2031) & (K Doses)
 Table 38. Asia Pacific Genetic Disorders Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Genetic Disorders Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Genetic Disorders Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Genetic Disorders Drug Sales by Country (2020-2025) & (K Doses)
 Table 42. Latin America Genetic Disorders Drug Sales by Country (2026-2031) & (K Doses)
 Table 43. Latin America Genetic Disorders Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Genetic Disorders Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Genetic Disorders Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Genetic Disorders Drug Sales by Country (2020-2025) & (K Doses)
 Table 47. Middle East and Africa Genetic Disorders Drug Sales by Country (2026-2031) & (K Doses)
 Table 48. Middle East and Africa Genetic Disorders Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Genetic Disorders Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Genetic Disorders Drug Sales (K Doses) by Type (2020-2025)
 Table 51. Global Genetic Disorders Drug Sales (K Doses) by Type (2026-2031)
 Table 52. Global Genetic Disorders Drug Sales Market Share by Type (2020-2025)
 Table 53. Global Genetic Disorders Drug Sales Market Share by Type (2026-2031)
 Table 54. Global Genetic Disorders Drug Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Genetic Disorders Drug Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Genetic Disorders Drug Revenue Market Share by Type (2020-2025)
 Table 57. Global Genetic Disorders Drug Revenue Market Share by Type (2026-2031)
 Table 58. Global Genetic Disorders Drug Price (USD/Dose) by Type (2020-2025)
 Table 59. Global Genetic Disorders Drug Price (USD/Dose) by Type (2026-2031)
 Table 60. Global Genetic Disorders Drug Sales (K Doses) by Application (2020-2025)
 Table 61. Global Genetic Disorders Drug Sales (K Doses) by Application (2026-2031)
 Table 62. Global Genetic Disorders Drug Sales Market Share by Application (2020-2025)
 Table 63. Global Genetic Disorders Drug Sales Market Share by Application (2026-2031)
 Table 64. Global Genetic Disorders Drug Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Genetic Disorders Drug Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Genetic Disorders Drug Revenue Market Share by Application (2020-2025)
 Table 67. Global Genetic Disorders Drug Revenue Market Share by Application (2026-2031)
 Table 68. Global Genetic Disorders Drug Price (USD/Dose) by Application (2020-2025)
 Table 69. Global Genetic Disorders Drug Price (USD/Dose) by Application (2026-2031)
 Table 70. Sanofi Company Information
 Table 71. Sanofi Description and Business Overview
 Table 72. Sanofi Genetic Disorders Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 73. Sanofi Genetic Disorders Drug Product
 Table 74. Sanofi Recent Developments/Updates
 Table 75. Vertex Company Information
 Table 76. Vertex Description and Business Overview
 Table 77. Vertex Genetic Disorders Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 78. Vertex Genetic Disorders Drug Product
 Table 79. Vertex Recent Developments/Updates
 Table 80. Takeda Company Information
 Table 81. Takeda Description and Business Overview
 Table 82. Takeda Genetic Disorders Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 83. Takeda Genetic Disorders Drug Product
 Table 84. Takeda Recent Developments/Updates
 Table 85. Amgen Company Information
 Table 86. Amgen Description and Business Overview
 Table 87. Amgen Genetic Disorders Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 88. Amgen Genetic Disorders Drug Product
 Table 89. Amgen Recent Developments/Updates
 Table 90. GW Pharmaceuticals Company Information
 Table 91. GW Pharmaceuticals Description and Business Overview
 Table 92. GW Pharmaceuticals Genetic Disorders Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 93. GW Pharmaceuticals Genetic Disorders Drug Product
 Table 94. GW Pharmaceuticals Recent Developments/Updates
 Table 95. Pfizer Company Information
 Table 96. Pfizer Description and Business Overview
 Table 97. Pfizer Genetic Disorders Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 98. Pfizer Genetic Disorders Drug Product
 Table 99. Pfizer Recent Developments/Updates
 Table 100. BioMarin Company Information
 Table 101. BioMarin Description and Business Overview
 Table 102. BioMarin Genetic Disorders Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 103. BioMarin Genetic Disorders Drug Product
 Table 104. BioMarin Recent Developments/Updates
 Table 105. Sarepta Company Information
 Table 106. Sarepta Description and Business Overview
 Table 107. Sarepta Genetic Disorders Drug Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 108. Sarepta Genetic Disorders Drug Product
 Table 109. Sarepta Recent Developments/Updates
 Table 110. Key Raw Materials Lists
 Table 111. Raw Materials Key Suppliers Lists
 Table 112. Genetic Disorders Drug Distributors List
 Table 113. Genetic Disorders Drug Customers List
 Table 114. Genetic Disorders Drug Market Trends
 Table 115. Genetic Disorders Drug Market Drivers
 Table 116. Genetic Disorders Drug Market Challenges
 Table 117. Genetic Disorders Drug Market Restraints
 Table 118. Research Programs/Design for This Report
 Table 119. Key Data Information from Secondary Sources
 Table 120. Key Data Information from Primary Sources
 Table 121. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Genetic Disorders Drug
 Figure 2. Global Genetic Disorders Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Genetic Disorders Drug Market Share by Type: 2024 & 2031
 Figure 4. Cystic Fibrosis (CF) Product Picture
 Figure 5. Duchenne Muscular Dystrophy (DMD) Product Picture
 Figure 6. Lysosomal Storage Disease (LSD) Product Picture
 Figure 7. Paroxysmal Nocturnal Hemoglobinuria (PNH) Product Picture
 Figure 8. Global Genetic Disorders Drug Market Value by Application (2020-2031) & (US$ Million)
 Figure 9. Global Genetic Disorders Drug Market Share by Application: 2024 & 2031
 Figure 10. Clinic
 Figure 11. Hospital
 Figure 12. Global Genetic Disorders Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Genetic Disorders Drug Market Size (2020-2031) & (US$ Million)
 Figure 14. Global Genetic Disorders Drug Sales (2020-2031) & (K Doses)
 Figure 15. Global Genetic Disorders Drug Average Price (USD/Dose) & (2020-2031)
 Figure 16. Genetic Disorders Drug Report Years Considered
 Figure 17. Genetic Disorders Drug Sales Share by Manufacturers in 2024
 Figure 18. Global Genetic Disorders Drug Revenue Share by Manufacturers in 2024
 Figure 19. Global 5 and 10 Largest Genetic Disorders Drug Players: Market Share by Revenue in Genetic Disorders Drug in 2024
 Figure 20. Genetic Disorders Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 21. Global Genetic Disorders Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 22. North America Genetic Disorders Drug Sales Market Share by Country (2020-2031)
 Figure 23. North America Genetic Disorders Drug Revenue Market Share by Country (2020-2031)
 Figure 24. U.S. Genetic Disorders Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Canada Genetic Disorders Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Europe Genetic Disorders Drug Sales Market Share by Country (2020-2031)
 Figure 27. Europe Genetic Disorders Drug Revenue Market Share by Country (2020-2031)
 Figure 28. Germany Genetic Disorders Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. France Genetic Disorders Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. U.K. Genetic Disorders Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Italy Genetic Disorders Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Russia Genetic Disorders Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Asia Pacific Genetic Disorders Drug Sales Market Share by Region (2020-2031)
 Figure 34. Asia Pacific Genetic Disorders Drug Revenue Market Share by Region (2020-2031)
 Figure 35. China Genetic Disorders Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Japan Genetic Disorders Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. South Korea Genetic Disorders Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. India Genetic Disorders Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Australia Genetic Disorders Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Taiwan Genetic Disorders Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Indonesia Genetic Disorders Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Thailand Genetic Disorders Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Malaysia Genetic Disorders Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Philippines Genetic Disorders Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Latin America Genetic Disorders Drug Sales Market Share by Country (2020-2031)
 Figure 46. Latin America Genetic Disorders Drug Revenue Market Share by Country (2020-2031)
 Figure 47. Mexico Genetic Disorders Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Brazil Genetic Disorders Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Argentina Genetic Disorders Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Middle East and Africa Genetic Disorders Drug Sales Market Share by Country (2020-2031)
 Figure 51. Middle East and Africa Genetic Disorders Drug Revenue Market Share by Country (2020-2031)
 Figure 52. Turkey Genetic Disorders Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Saudi Arabia Genetic Disorders Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. U.A.E Genetic Disorders Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. Global Sales Market Share of Genetic Disorders Drug by Type (2020-2031)
 Figure 56. Global Revenue Market Share of Genetic Disorders Drug by Type (2020-2031)
 Figure 57. Global Genetic Disorders Drug Price (USD/Dose) by Type (2020-2031)
 Figure 58. Global Sales Market Share of Genetic Disorders Drug by Application (2020-2031)
 Figure 59. Global Revenue Market Share of Genetic Disorders Drug by Application (2020-2031)
 Figure 60. Global Genetic Disorders Drug Price (USD/Dose) by Application (2020-2031)
 Figure 61. Genetic Disorders Drug Value Chain
 Figure 62. Channels of Distribution (Direct Vs Distribution)
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Novocure